Home
>
US Stocks
>
Cabaletta Bio Inc
Cabaletta Bio Inc
CABA

Cabaletta Bio Inc (CABA)

$12.933.68%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
13.01
Today Low/High
12.6 / 13.73
52 Week Low/High
$7 / $16.38
Market Cap
$185.05M

Company Details

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. The Company's lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
Organisation
Cabaletta Bio Inc
Employees
34
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Cabaletta Bio Inc (CABA) share price today?

Can Indians buy Cabaletta Bio Inc (CABA) shares?

How can I buy Cabaletta Bio Inc (CABA) shares from India?

Can Fractional shares of Cabaletta Bio Inc (CABA) be purchased?

What are the documents required to start investing in Cabaletta Bio Inc (CABA) stocks?

We are a SEBI registered investement advisor